Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carla M, Van Herpen"'
Autor:
Marije J, Klumpers, Ward De, Witte, Giovanna, Gattuso, Elisabetta, Schiavello, Monica, Terenziani, Maura, Massimino, Corrie E M, Gidding, Sita H, Vermeulen, Chantal M, Driessen, Carla M, Van Herpen, Esther, Van Meerten, Henk-Jan, Guchelaar, Marieke J H, Coenen, D Maroeska W M, Te Loo
Publikováno v:
Journal of personalized medicine. 12(6)
Nephrotoxicity is a common and dose-limiting side effect of platinum compounds, which often manifests as acute kidney injury or hypomagnesemia. This study aimed to investigate the genetic risk loci for platinum-induced nephrotoxicity. Platinum-treate
Autor:
Loes H C, Nissen, Lauranne A A P, Derikx, Anouk M E, Jacobs, Carla M, van Herpen, Wietske, Kievit, Rob, Verhoeven, Esther, van den Broek, Elise, Bekers, Tim, van den Heuvel, Marieke, Pierik, Janette, Rahamat-Langendoen, Robert P, Takes, Willem J G, Melchers, Iris D, Nagtegaal, Frank, Hoentjen, W, Bruins Slot
Publikováno v:
Inflammatory Bowel Diseases, 24(9), 2015-2026. LIPPINCOTT WILLIAMS & WILKINS
Inflammatory Bowel Diseases, 24, 9, pp. 2015-2026
Inflammatory bowel diseases, 24(9), 2015-2026. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 24, 2015-2026
Inflammatory Bowel Diseases, 24, 9, pp. 2015-2026
Inflammatory bowel diseases, 24(9), 2015-2026. John Wiley and Sons Inc.
Inflammatory Bowel Diseases, 24, 2015-2026
Background: Immunosuppressed inflammatory bowel disease (IBD) patients are at increased risk to develop extra-intestinal malignancies. Immunosuppressed transplant patients show increased incidence of head and neck cancer with impaired survival. This
Autor:
Carla M, Van Herpen, Richard, Huijbens, Maaike, Looman, Jolanda, De Vries, Henri, Marres, Johanna, Van De Ven, Rob, Hermsen, Gosse J, Adema, Pieter H, De Mulder
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(8)
The aim of this study was to evaluate the tolerability of intratumoral administered recombinant human interleukin-12 (rhIL-12) in patients with head and neck squamous cell carcinoma. Six patients were treated once a week at two dose levels of 100 or